• Ertugliflozin and Tau in Brain Insulin Resistance

  2026-09-17

  This study evaluates ertugliflozin in an intracerebroventricular streptozotocin rat model and links improved cognition with reduced hippocampal tau hyperphosphorylation. Its main contribution is a mechanistic framework connecting disrupted IRS-1/Akt/GSK3β signaling with cholinergic, mitochondrial, apoptotic, and synaptic abnormalities.

• Viral RIPK3 Degradation and Neddylation Biology

  2026-09-17

  Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that links orthopoxvirus immune evasion to the host SCF ubiquitin-ligase machinery. The study shows that viral control of RIPK3-dependent necroptosis can alter inflammation, replication, and disease severity, providing a mechanistic framework for examining neddylation-dependent protein degradation in infection and cancer biology research.

• From Metabolic Mechanism to qPCR Confidence

  2026-09-16

  The dAGE-exposed mouse study of myriocin illustrates how metabolic phenotypes become translationally useful only when pathway-level measurements are specific, reproducible, and biologically coherent. This article connects AMPK–PGC1α signaling, hepatic lipid regulation, adipose thermogenesis, and qPCR assay strategy, showing how HotStart™ 2X Green qPCR Master Mix can support real-time PCR gene expression analysis, RNA-seq validation, and nucleic acid quantification while preserving appropriate scientific caution.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-09-16

  This scenario-based guide explains how HotStart™ 2X Green qPCR Master Mix, SKU K1070, can support reproducible gene-expression measurements alongside cell viability, proliferation, and cytotoxicity assays. It covers assay compatibility, hot-start specificity, protocol controls, interpretation, and practical supplier selection.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-09-15

  HotStart™ 2X Green qPCR Master Mix provides a SYBR Green format for real-time amplification of cDNA or DNA while using antibody-mediated Taq polymerase hot-start inhibition to help limit early nonspecific products. It is suitable for gene expression, RNA-seq validation, and nucleic acid quantification, but assay-specific cycling conditions, primer performance, and melt-curve specificity must be validated in the user’s system.

• Reactive Oxygen Species Assay Kit Workflow

  2026-09-15

  Build a reproducible live-cell ROS workflow with DCFH-DA, positive-control validation, and normalization strategies. The assay is especially useful for connecting treatment-induced oxidative stress with apoptosis, DNA damage, and FLASH-radiotherapy sensitization studies.

• DNase I (RNase-free) for Assay Reliability

  2026-09-14

  This scenario-driven guide shows how DNase I (RNase-free), SKU K1088, can reduce DNA-related confounding in RNA, RT-PCR, transcription, and cancer-cell assay workflows. It connects practical controls with evidence from colorectal cancer resistance research while distinguishing documented product features from laboratory recommendations.

• Tacrolimus (FK506) in Immunometabolic Assays

  2026-09-14

  Tacrolimus (FK506) is more than a calcineurin inhibitor: it can serve as a precise perturbation tool for separating cytokine signaling from metabolic-stress responses. This article connects FK506 assay design with AMPK–SQSTM1 biology while defining practical controls, dosing logic, and experimental limitations.

• Salvianolic Acid B and LH2 in Pulmonary Fibrosis

  2026-09-13

  The reference study identifies Salvianolic acid B, also known as Dan Shen Suan B, as a candidate antifibrotic compound that reduces LH2-associated collagen remodeling in pulmonary fibrosis models. Its integrated cellular and tissue-level design links LH2 expression with epithelial–mesenchymal transition, fibroblast activation, Wnt/β-catenin signaling, collagen deposition, and lung architecture, while also highlighting the need for further target-engagement and translational studies.

• GANT61: Practical GLI Inhibition Workflows

  2026-09-12

  GANT61 is a selective GLI inhibitor for connecting Hedgehog pathway output with cancer-cell phenotypes, including transcriptional control, chemotherapy response, and ferroptosis-related assays. This workflow-focused guide shows how to prepare the compound, design concentration and time-course studies, and interpret GLI2–PRDX1 findings without overstating pathway specificity.

• A-1331852: A Precision BCL-XL Inhibitor Workflow

  2026-09-12

  A-1331852 is a selective BCL-XL inhibitor for connecting target engagement with apoptosis, senescence elimination, and combination cancer research. This practical guide translates published BH3-mimetic findings into assay design, dosing, controls, and troubleshooting while clearly separating established evidence from workflow recommendations.

• Mechanistic qPCR for Translational Virology

  2026-09-11

  Mechanistic findings in hepatitis D virus biology show why replication and assembly should be measured as related but distinct endpoints. This article translates those insights into a practical SYBR Green qPCR strategy, positioning HotStart™ 2X Green qPCR Master Mix for reproducible real-time PCR gene expression analysis, nucleic acid quantification, and RNA-seq validation while clarifying the limits of dye-based assays.

• AG-490: A Causal Map for JAK2/STAT6 Assays

  2026-09-11

  AG-490 (Tyrphostin B42) can help researchers test how exosomal SNORD52 reshapes JAK2/STAT6-dependent macrophage states in hepatocellular carcinoma. This article presents a causal, compartment-aware assay strategy that separates pathway inhibition from exosome transfer and cell-state effects.

• From Fluorescence to Translational RNA Delivery

  2026-09-10

  A mechanistic and strategic guide to using ARCA EGFP mRNA as a direct readout for delivery, translation, and formulation decisions, including how reporter data can inform lipid nanoparticle development without overstating what a fluorescence signal proves.

• ABT-199: Reliable Apoptosis Assay Workflows

  2026-09-10

  A scenario-driven guide to using ABT-199 (GDC-0199), Bcl-2 inhibitor, potent and selective (SKU A8194) in viability and apoptosis studies. It connects BCL-2 selectivity, DMSO handling, assay controls, and interpretation across hematologic malignancy models.

8664 records 1/578 page Next 12345 下5页 Last page